Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript

SA Transcripts 162.07K Followers Follow Shield Therapeutics plc ( SHIEF ) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR September 1, 2026 9:15 AM EDT Company Participants Anders Lundstrom - CEO & Director Andrew Hurley - Chief Commercial Officer Bryon Kallert - Senior Director of Financial Planning & Analysis Presentation Unknown Attendee I think we've got a good number of people joining now to kick off today. So good afternoon, and welcome to the Shield Therapeutics webinar, where the team will be providing an update on Shield assuming full control of ACCRUFeR in the U.S. [Operator Instructions] The company might not be in a position to answer every question submitted today and, where appropriate, share a response following today's presentation. The webinar today is being recorded, and we will be publishing this on the Shield Therapeutics website after today. I'd like to hand over now to Shield Therapeutics CEO, Anders; CCO, Andy; and Bryon, Senior Director of FP&A. Anders Lundstrom CEO & Director Thank you, Polly, and good afternoon, good morning, everyone, and thank you for joining us. I'm Anders Lundstrom. And as Polly said, I'm also joined by Andy Hurley, our Chief Commercial Officer; and Bryon Kallert, our Senior Director of Financial Planning and Analysis. As many of you will have seen, we announced last Thursday, we have reached an agreement with Viatris, our current U.S. partner, to assume full control of ACCRUFeR in the U.S. So this is a landmark opportunity for our company, and we're glad we have this opportunity to walk you through it more in detail. So the purpose of today's call is to explain as clearly and fully as we can why we believe this is such a significant milestone for Shield Therapeutics. Next slide, please. Before we begin, please note that the disclaimer on the slide regarding the forward-looking statements. We'll start with a